Healthcare / BiotechnologyShenzhen
$9.23
+0.03 (+0.33%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $70.1M · quality 49.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.5B
P/E
22.5x
↑EV/EBITDA
10.5x
↓ROE
6.7%
↑Gross Margin
13.3%
↓Debt/Equity
0.05
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+0.5%
FCF CAGR
—
FCF margin
2.5%
FCF / Net income
0.47x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.75B · net income $150.6M · FCF $70.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.75B | $2.75B | $2.40B | $2.52B | $2.71B |
| Net Income | $150.6M | $150.6M | $111.2M | $54.0M | $133.2M |
| EBITDA | $307.2M | $307.2M | $263.7M | $210.5M | $288.9M |
| EPS | 0.41 | 0.41 | 0.30 | 0.15 | 0.36 |
| Gross Margin | 13.3% | 13.3% | 11.9% | 8.1% | 11.5% |
| Operating Margin | 6.9% | 6.9% | 6.7% | 3.6% | 6.2% |
| Net Margin | 5.5% | 5.5% | 4.6% | 2.1% | 4.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.05 | 0.05 | 0.13 | 0.15 | 0.25 |
| Current Ratio | 1.79 | 1.79 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $70.1M | $70.1M | $58.8M | $130.1M | $-223.7M |
| Returns | |||||
| ROE | 6.7% | 6.7% | 5.4% | 2.7% | 6.6% |
| Valuation | |||||
| P/E | 22.51 | 22.51 | 23.73 | 54.27 | 24.31 |
| EV/EBITDA | 10.52 | 10.52 | 10.07 | 14.15 | 11.66 |
| P/B | 1.52 | 1.52 | 1.29 | 1.48 | 1.61 |
| Growth & Yield | |||||
| Revenue Growth | 14.5% | 14.5% | -4.8% | -7.0% | — |
| EPS Growth | 36.7% | 36.7% | 100.0% | -58.3% | — |
| Dividend Yield | 1.0% | 1.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
25.9%
EPS terminal req.
$0.82
Spread vs growth
10.7%
5Y implied EPS CAGR
19.3%
EPS terminal req.
$0.99
Spread vs growth
17.4%
10Y implied EPS CAGR
14.6%
EPS terminal req.
$1.60
Spread vs growth
22.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-18.1%
Start / end P/E
38.1x → 22.5x
EPS bridge
0.30 → 0.41
Residual
-15.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.